Introduction:
PharmaBlock plans to expand its R&D operations to deliver GMP projects with the opening of new facility.
Features:
This expanded footprint will enable to more efficiently process R&D services for the rapid delivery of clinical-phase GMP projects to global partners.
The state-of-the-art facility will provide clients with the highest quality research and development solutions. It joins the existing facility and enhance the delivery of clinical-stage API projects.
The new site cosnisting of 30,000 ft2 of laboratory space also includes process research and development laboratories, GMP suites, clean rooms and GMP analytical laboratories. Moreover, the facility allows for flow chemistry, micro-packed bed hydrogenation, and solid-state chemistry capabilities.
In addition, a GMP production facility for intermediates and APIs with 500-2,000 litre reactors are planned for the West Chester plant, which is expected to be operational in 2024.
Specifications:
Name PharmaBlock
Type New Construction
